Department of Medical Oncology, Guy's & St Thomas NHS Foundation Trust, London, UK.
Institute of Cancer Policy, King's College London, London, UK.
Br J Cancer. 2023 Apr;128(8):1409-1414. doi: 10.1038/s41416-023-02224-y. Epub 2023 Mar 23.
The COVID-19 pandemic posed significant risk to the health of cancer patients, compromised standard cancer care and interrupted clinical cancer trials, prompting dramatic streamlining of services. From this health crisis has emerged the opportunity to carry forward an unexpected legacy of positive reforms to clinical cancer research, where conventionally convoluted approvals processes, inefficient trial design, procedures and data gathering could benefit from the lessons in rationalisation learned during the pandemic.
COVID-19 大流行给癌症患者的健康带来了重大风险，影响了标准的癌症治疗并中断了临床癌症试验，促使服务大幅简化。这场卫生危机带来了一个意想不到的机会，可以将临床癌症研究中的积极改革延续下去，在这些研究中，传统上复杂的审批流程、效率低下的试验设计、程序和数据收集都可以从大流行期间学到的合理化经验中受益。
